Latest Articles


Editorial

Nanoparticles could Improve the Efficiency of CAR-T Immunotherapy for Cancer

CAR-T immunotherapies are the cutting-edge topics of research and investment recently.

Published 06 Sep, 2018


Editorial

Toward Epigenome-Based Personalized Therapeutic Strategies in Myelodysplastic Syndromes: Current Concepts and Future Landscapes

Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders, characterized by impaired hematopoiesis and a propensity to progress into Acute Myeloid Leukemia (AML), leading to significant morbidity and mortality [1].

Published 01 Sep, 2018


Case Report

Complete Resolution of Steroid-Refractory Acute Graft-Versus-Host Disease using Alemtuzumab after Haplo-Identical Transplant

Acute Graft versus Host Disease (aGvHD) is a serious complication after allogeneic Hematopoietic Stem Cell Transplant (allo-SCT).

Published 24 May, 2018


Case Report

Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia

Relapsed Philadelphia chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL) is an aggressive lymphoid malignancy with a poor prognosis and no randomized studies demonstrating superiority of any single salvage regimen.

Published 23 Mar, 2018


Editorial

Highlights from the 2017 American Society of Hematology (ASH) Meeting: Therapy of Chronic Lymphocytic Leukemia

MyelodysplasticThe treatment of Chronic Lymphocytic Leukemia (CLL) has undergone significant changes based on patients’ genetic status, mutation status and with the introduction of the B-cell receptor inhibitors.

Published 20 Feb, 2018


Case Report

Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne

Myelodysplastic Syndrome (MDS) is a diverse group of clonal hematologic neoplasms. The only curative treatment for MDS is allogeneic Stem Cell Transplantation (SCT).

Published 25 Jan, 2018


Review Article

CAR-T – The Future Promising Therapy for CLL: A Mix between Cell Therapy, Gene Therapy and Immune-Oncology

Chronic lymphocytic leukemia (CLL) has considerable change since the time clinical staging was introduced in clinical practice in 1975.

Published 08 Sep, 2017


Editorial

Small Molecule Inhibitors: Suitable Drugs for Targeted-Based Cancer Therapy

Cancer has appeared as the main disease and leading cause of death after cardiovascular disorders and has been described as a complicated disease of uncontrolled cell proliferation [1].

Published 02 Aug, 2017


Editorial

The AP-1 Family Member JunB: A Novel Potential Target for Therapy in Multiple Myeloma

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by clonal expansion of plasma cell within the bone marrow (BM), and is often preceded by a premalignant condition named gammopathy of undetermined significance (MGUS), defined by the presence of serum monoclonal protein <30 g/L, clonal BM plasma cells <10%, in the absence of renal failure, anemia, bone lesions, hypercalcemia, or amyloidosis [1].

Published 06 Jul, 2017


Editorial

Back to Normal Life: Pregnancy and CML

Since the introduction in the new century of the tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia, the whole approach to the illness has changed very quickly.

Published 24 Jun, 2017


Editorial

Cyclooxygenase-2 and Apoptosis Resistance in Hematological Malignancies

During the 80s, the interest concerned to prostaglandins and their role in the inhibition of hematopoietic progenitors proliferation.

Published 17 Jun, 2017


Editorial

Role of KIR and HLA in Donor Selection for HSCT

Majority of the patients with hematological diseases lacking human leukocyte antigen (HLA) matched sibling donors are treated by hematopoietic stem cells transplantation (HSCT) from HLA matched unrelated donors.

Published 12 May, 2017





SHARE THIS ARTICLE


Renowned Editors

MIT, John Hopkins University, Stanford University, University of Michigan...300+

Rapid Peer Review

We assure 20 days rapid peer review process

Open Access

Open Access is the free, immediate, online availability of novel research

High Visibility

Published articles are easy to find on google, google scholar and other databases